ANDROGEL 16,2 mg/g Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

androgel 16,2 mg/g

laboratoires besins international s.a.s. - franta - testosteronum - gel - 16,2mg/g - androgeni derivati de 3-oxoandrosten (4)

Innovax-ND-IBD Den Europæiske Union - rumænsk - EMA (European Medicines Agency)

innovax-nd-ibd

intervet international b.v. - celule asociate viu recombinant turcia herpesvirus (tulpina hvp360), exprimarea proteinei de fuziune a nd virus și vp2 proteine de ibd virus - aviare, virusul herpes (marek boala lui) + virusul bursitei infecțioase aviare (boala de gumboro) + virusul bolii de newcastle/paramixovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

OXALIPLATIN KABI 5 mg/ml Rumænien - rumænsk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

oxaliplatin kabi 5 mg/ml

fresenius kabi deutschland gmbh - germania - oxaliplatinum - conc. pt. sol. perf. - 5mg/ml - alte antineoplazice compusi de platina

Oxaliplatin 100 mg pulbere pentru soluţie perfuzabilă Moldova - rumænsk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

oxaliplatin 100 mg pulbere pentru soluţie perfuzabilă

naprod life sciences private limited - oxaliplatinum - pulbere pentru soluţie perfuzabilă - 100 mg

Zolgensma Den Europæiske Union - rumænsk - EMA (European Medicines Agency)

zolgensma

novartis europharm limited  - onasemnogene abeparvovec - atrofia musculară, spinală - alte medicamente pentru tulburări ale sistemului musculo-scheletic - zolgensma este indicat pentru tratamentul:pacienții cu 5q atrofie musculară spinală (sma), cu un bi-alelică mutație în gena smn1 și un diagnostic clinic de sma tip 1, orpatients cu ams 5q cu un bi-alelică mutație în gena smn1 și până la 3 copii ale genei smn2.

Phelinun Den Europæiske Union - rumænsk - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agenți antineoplazici - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.